Cancer Stem Cells and Mechanisms of Multi-Drug Resistance by Flow Cytometry


Dr. Jordi Petriz, Principal Investigator, Jose Carreras Leukemia Research Institute (IJC) discusses how flow cytometry can be a key player in investigating cancer stem cells.

Image for Cancer Stem Cells and Mechanisms of Multi-Drug Resistance by Flow Cytometry

Who should attend:1. Those needing a more complete understanding of the complexities involved in the analysis of rare cells by flow cytometry 2. Bench scientists and clinicians who need to become knowledgeable about designing experiments or studies in which functional flow cytometry will be used


The cancer stem cell (CSC) model has been established as a cellular mechanism that contributes to phenotypic and functional heterogeneity in diverse cancer types. Recent observations, however, have highlighted many complexities and challenges: the CSC phenotype can vary substantially between patients, tumors may harbor multiple phenotypically or genetically distinct CSCs, metastatic CSCs can evolve from primary CSCs, and tumor cells may undergo reversible phenotypic changes. Although the CSC concept will have clinical relevance in specific cases, accumulating evidence suggests that it will be imperative to target all CSC subsets within the tumor to prevent relapse. In cancer therapy, detailed understanding of the effects of drugs on signal transduction pathways in the target cells is of pivotal relevance in tailoring individualized therapeutic approaches. Furthermore, new and more detailed diagnostics will help to specifically design a therapy for the individual patient.

In this webinar, Dr. Jordi Petriz (The Jose Carreras Leukemia Research Institute in Barcelona) will discuss how flow cytometry can be a key player in these endeavors. A characteristic of ‘‘stemness’’ of normal and tumor stem cells is their ability to express transporter molecules that function to exclude anticancer drugs and certain dye molecules very helpful to prospectively identify and isolate cancer stem cells by flow cytometry.

Key Highlights:

  1. The Primary Challenges Encountered in Drug Resistance to Anticancer Agents
  2. Methods for Preparing Multidrug Resistance Assays, including Identification of Primitive Stem Cells
  3. The Types of Information that can be Obtained using this Technology

Presenter(s)

Dr. Jordi Petriz - The Jose Carreras Leukemia Research Institute, Spain, Barcelona

Dr. Jordi Petriz

The Jose Carreras Leukemia Research Institute, Spain, Barcelona

Jordi Petriz has authored or co-authored nearly 100 research contributions; some in high impact Journals including Nature Medicine and Leukemia. He has been the President of the Iberian Society for Cytometry (SIC) since 2007.Jordi Petriz received his BSc degree in biochemistry and animal biology from the University of Barcelona. He then pursued his PhD at Barcelona after acceptance at the Cryobiology and Cell Therapy Department, Cancer Research Institute. In 1998 he obtained his PhD degree in physiology and immunology specializing in functional-based mechanisms on multidrug resistance against anticancer agents. The cytomic functional approach was used to account for multidrug transporters and drug resistance profiling in highly refractory cancer cells. As a postdoctoral fellow he applied new cytomic approaches to address questions on whole blood counting of CD34+ progenitor cells. In 2000, he joined the Subcommittee on Quality Assessment of Hematopoietic Stem Cell Grafts (established by the European Group for Bone Marrow Transplantation). Since then he has become a Principal Investigator at the IJC.